Drug intelligence / Profile preview

Allefin

Development stage
Unknown
Lead developer
Hasco-Lek
Modality
Small Molecules
Administration
Topical
01

Overview

**Allefin** is a Polish fixed-dose topical gel developed and manufactured by Hasco-Lek. Each gram contains diphenhydramine hydrochloride 20 mg, a first-generation H1 antihistamine that suppresses histamine-mediated itch and allergic skin responses, and lidocaine hydrochloride 10 mg, a local anesthetic that blocks voltage-gated sodium channels to provide local analgesia. It is indicated for symptomatic treatment of pruritic contact allergic and inflammatory skin lesions caused by external exposures, including insect and arachnid bites or stings, contact with plants such as nettles or ivy, and jellyfish stings; it is used in adults, adolescents, and children aged 2 years and older. ([rejestrymedyczne.ezdrowie.gov.pl](https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/38703/leaflet))

Brand names
Allefin
02

Targets

NaV (Voltage-gated sodium channels)KCNH2 (Voltage-gated potassium channel subfamily H member 2)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Allefin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allefin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call